SCHEMBL1372387

SCHEMBL1372387

O=C(Nc1ccc(Oc2ccc(F)cc2)cc1)[C@@H]1C[C@@H](c2ccccc2)CN1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 2/20 0.51
CYP3A4 P08684 1/20 0.51
CYP2D6 P10635 1/20 0.51
CYP2C9 P11712 1/20 0.51
HDAC2 Q92769 2/20 0.47
GRIN2B Q13224 1/20 0.46
RPS6KB1 P23443 1/20 0.44
EPHX2 P34913 1/20 0.44
FNTA P49354 2/20 0.44
FNTB P49356 2/20 0.44
MEN1 O00255 1/20 0.44
LMNA P02545 1/20 0.44
KMT2A Q03164 1/20 0.44
MMP13 P45452 3/20 0.43
MMP2 P08253 2/20 0.42
MMP1 P03956 1/20 0.42
MMP3 P08254 1/20 0.42
MMP9 P14780 1/20 0.42
NPC1 O15118 1/20 0.42
TP53 P04637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2170273 1.00 S1PR1 (0.51) S1PR1CYP3A4CYP2D6CYP2C9HDAC2
SCHEMBL2171912 0.89 FPR2 (0.48) S1PR1CYP3A4CYP2D6CYP2C9EPHX2
SCHEMBL1375586 0.89 FPR2 (0.48) S1PR1CYP3A4CYP2D6CYP2C9EPHX2
SCHEMBL2355325 0.83 HRH3 (0.47) S1PR1CYP3A4CYP2D6CYP2C9EPHX2
SCHEMBL1372130 0.82 EPHX2 (0.48) S1PR1CYP3A4CYP2D6CYP2C9EPHX2
SCHEMBL2169869 0.82 EPHX2 (0.48) S1PR1CYP3A4CYP2D6CYP2C9EPHX2
SCHEMBL1375039 0.82 EPHX2 (0.48) S1PR1CYP3A4CYP2D6CYP2C9EPHX2
SCHEMBL1373852 0.82 EPHX2 (0.48) S1PR1CYP3A4CYP2D6CYP2C9EPHX2
SCHEMBL1371656 0.81 S1PR1 (0.53) S1PR1CYP3A4CYP2D6CYP2C9EPHX2
SCHEMBL3129745 0.81 EPHX2 (0.45) S1PR1CYP3A4CYP2D6CYP2C9EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8791102-B2 Acetanilide sphingosine-1-phosphate receptor antagonists EXELIXIS, INC. (US) 2014-07-29 US disclosed
US-20110288076-A1 Sphingosine-1-Phosphate Receptor Antagonists EXELIXIS, INC. (US) 2011-11-24 US disclosed
EP-2346821-A1 SPHINGOSINE-1-PHOSPHATE RECEPTOR ANTAGONISTS Exelixis, Inc. (US) 2011-07-27 EP disclosed
WO-2010045580-A1 SPHINGOSINE-1-PHOSPHATE RECEPTOR ANTAGONISTS EXELIXIS, INC. (US) 2010-04-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110288076-A1 Sphingosine-1-Phosphate Receptor Antagonists S1PR1, S1PR2, S1PR3 S1PR1 1/4885CYP3A4 4784/4885CYP2D6 4804/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.